May 29, 2025
A joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in Canada
Feb 27, 2025
Slynd is now available to 95% of the Canadian population under public insurance plans
Nov 30, 2020
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®
Mar 05, 2019
Duchesnay USA Pledges Continued Support of the Mobile Mom Squad through Donations of its Mteryti® and Mteryti® folic 5 Prenatal Supplements
Jan 29, 2019
Duchesnay Inc. Receives Approval of Supplemental New Drug Application (sNDA) to Add Moderate to Severe Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause, to the Indication of Osphena® (ospemifene)
Oct 23, 2018
Duchesnay Inc. Announces Submission of Supplemental New Drug Application (sNDA) for Osphena® (ospemifene) to U.S. FDA Seeking Approval for the Treatment of Vaginal Dryness, a Symptom of Vulvar and Vaginal Atrophy (VVA) Due to Menopause
Sep 14, 2018
Duchesnay Inc. to Present a Poster on Adherence, Persistence and Healthcare Costs Associated with Ospemifene at 2018 Annual Meeting of the North American Menopause Society (NAMS)
Sep 13, 2018
Duchesnay Inc. to Present a Poster on Ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS)
Sep 12, 2018
Duchesnay Inc. to Present a Poster on the Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness at 2018 Annual Meeting of the North American Menopause Society (NAMS)
Jun 07, 2018
Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder
May 30, 2018
Menopausal Women Staying Silent About Painful Sex - Recent Survey Highlights Knowledge Gap About Treatment Options
Apr 25, 2018
Duchesnay, Inc. Announces Presentation of Abstract at 16th World Congress on Menopause
Apr 02, 2018
Duchesnay USA Announces Launch of Bonjesta® (doxylamine succinate - pyridoxine hydrochloride) in the United States